Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Liabilities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Total Liabilities for 14 consecutive years, with $29.9 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 34.66% to $29.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.9 million through Dec 2025, up 34.66% year-over-year, with the annual reading at $29.9 million for FY2025, 34.66% up from the prior year.
  • Total Liabilities for Q4 2025 was $29.9 million at Niagen Bioscience, up from $27.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $29.9 million in Q4 2025, with the low at -$43.8 million in Q1 2021.
  • Average Total Liabilities over 5 years is $22.1 million, with a median of $25.8 million recorded in 2022.
  • Peak annual rise in Total Liabilities hit 228.31% in 2021, while the deepest fall reached 329.94% in 2021.
  • Over 5 years, Total Liabilities stood at $26.1 million in 2021, then decreased by 2.79% to $25.4 million in 2022, then grew by 4.42% to $26.5 million in 2023, then decreased by 16.31% to $22.2 million in 2024, then skyrocketed by 34.66% to $29.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $29.9 million, $27.5 million, and $27.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.